The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough designation.

While neither AstraZeneca nor Avillion has revealed plans to seek marketing approval for the treatment, results from the study are a positive sign for the asthma pipeline. Asthma is an ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand ...

Of the other antidiabetic medications evaluated ... the Research Grant Council, AstraZeneca, Chiesi, GSK, the Asthma UK Centre for Applied Research, and Asthma + Lung UK. Cahill reported financial ...

The pharma giant recently announced a partnership with the Professional Pickleball Association (PPA) to help raise awareness for its eosinophilic asthma biologic Fasenra. The collaboration is a ...

The major Severe Asthma companies iin the market such as AstraZeneca, Sanofi, Teva, GSK, Regeneron, Amgen, Ellodi, Bristol Myers Squibb, Revolo, EsoCap, and Pfizer, is expected to transform with ...